Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes ...Middle East

This study is the third ATG-016 study to be conducted in China. Study highlights Antengene's robust SINE programs. SHANGHAI and HONG KONG, March 29, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global...

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes )

Also on site :

• Anne Burrell's Husband Looks Somber in First Photo Since Food Network Star's Death
• Iran threatens US bases in Middle East, asserts nuclear facilities undamaged
• Las negociaciones “no tienen sentido” a menos que Israel detenga los ataques, dice un portavoz del Gobierno iraní a CNN